NCT04518969 is a NA clinical trial of CytoSorb in Covid19, sponsored by Dr David DE BELS.

Who is sponsoring NCT04518969?

NCT04518969 is sponsored by Dr David DE BELS.

What drugs are being tested in NCT04518969?

Interventions in NCT04518969: CytoSorb.

Is NCT04518969 still recruiting?

NCT04518969 is currently completed. Last updated 4 March 2022.

Last reviewed 2022-03-04 · How we verify

NCT04518969

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19

Completed NA Last updated 4 March 2022

What this trial tests

NA trial testing CytoSorb in Covid19 in 24 participants. Completed in 16 September 2021.

Timeline

3 May 2020

Primary endpoint
16 September 2021

16 September 2021

Quick facts

Lead sponsor	Dr David DE BELS
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	3 May 2020
Primary completion	16 September 2021
Estimated completion	16 September 2021
Sites	1 location across Belgium

Drugs / interventions tested

CytoSorb

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Dr David DE BELS

Who can join

Adults 18 to 80, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A) Comparing the % of change in each clearances of pro-, and anti-inflammatory mediators (cytokine, chemokines and complement) in the COVID-19 patients treated with CytoSorb as compared to the same patient population who do not receive blood purification treatment. B) Testing the Cytokinetic model by measuring cytokines in the blood stream and in the BAL to see if you can create a reverse gradient allowing a massive passage of leucocyte from the blood toward the infected lungs.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta-analysis of randomized controlled trials.
Heymann M, Schorer R, Putzu A. · · 2022 · cited 32× · PMID 35788557 · DOI 10.1111/aas.14115
A Review of Extracorporeal Blood Purification Techniques for the Treatment of Critically Ill Coronavirus Disease 2019 Patients.
Niazi NS, Nassar TI, Stewart IJ, Honore PM, et al · · 2022 · cited 18× · PMID 35417433 · DOI 10.1097/mat.0000000000001761
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.
Xue Y, Mei H, Chen Y, Griffin JD, et al · · 2023 · cited 9× · PMID 37193304 · DOI 10.1002/mco2.254
Blood purification could tackle COVID-19?
Yamada H, Ohtsuru S. · · 2021 · cited 6× · PMID 34895343 · DOI 10.1186/s40560-021-00586-0
EFFICACY OF SUPPLEMENTAL HEMOADSORPTION THERAPY ON SEVERE AND CRITICAL PATIENTS WITH COVID-19: AN EVIDENCE-BASED ANALYSIS.
He J, Lin Y, Cai W, Lin Y, et al · · 2023 · cited 4× · PMID 37548606 · DOI 10.1097/shk.0000000000002189

Verify or expand the search:

Other trials of CytoSorb

Trials testing the same drug.

NCT06079021 — COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device · NA · recruiting
NCT05242289 — Cytokine Adsorption in Lung Transplantation · NA · completed
NCT05259514 — CytoSorb SAH Trial · NA · terminated
NCT05077124 — Safe and Timely Antithrombotic Removal (STAR) Registry · recruiting
NCT05027529 — ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock · NA · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Dr David DE BELS trials

Trials by the same sponsor.

NCT04024007 — Determination of Citrate Clearance Used in Regional Anticoagulation of Continuous Venous Hemofiltration Circuits · unknown
NCT04022603 — Impact of High-level Oxygen Therapy on the Reconditioning of Type I Hypoxemic Respiratory Insufficiency Patients in Inte · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04518969 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr David DE BELS
Last refreshed: 4 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04518969.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing